Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis.

Fabregat I, Caballero-Díaz D.

Front Oncol. 2018 Sep 10;8:357. doi: 10.3389/fonc.2018.00357. eCollection 2018. Review.

2.

Revisiting the liver: from development to regeneration - what we ought to know!

López-Luque J, Fabregat I.

Int J Dev Biol. 2018;62(6-7-8):441-451. doi: 10.1387/ijdb.170264JL.

PMID:
29938756
3.

Bone morphogenetic protein 9 as a key regulator of liver progenitor cells in DDC-induced cholestatic liver injury.

Addante A, Roncero C, Almalé L, Lazcanoiturburu N, García-Álvaro M, Fernández M, Sanz J, Hammad S, Nwosu ZC, Lee SJ, Fabregat I, Dooley S, Ten Dijke P, Herrera B, Sánchez A.

Liver Int. 2018 Sep;38(9):1664-1675. doi: 10.1111/liv.13879. Epub 2018 May 25.

PMID:
29751359
4.

TGF-β and the Tissue Microenvironment: Relevance in Fibrosis and Cancer.

Caja L, Dituri F, Mancarella S, Caballero-Diaz D, Moustakas A, Giannelli G, Fabregat I.

Int J Mol Sci. 2018 Apr 26;19(5). pii: E1294. doi: 10.3390/ijms19051294. Review.

5.

Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression.

Rani B, Malfettone A, Dituri F, Soukupova J, Lupo L, Mancarella S, Fabregat I, Giannelli G.

Cell Death Dis. 2018 Mar 7;9(3):373. doi: 10.1038/s41419-018-0384-5.

6.

Redox stress in Marfan syndrome: Dissecting the role of the NADPH oxidase NOX4 in aortic aneurysm.

Jiménez-Altayó F, Meirelles T, Crosas-Molist E, Sorolla MA, Del Blanco DG, López-Luque J, Mas-Stachurska A, Siegert AM, Bonorino F, Barberà L, García C, Condom E, Sitges M, Rodríguez-Pascual F, Laurindo F, Schröder K, Ros J, Fabregat I, Egea G.

Free Radic Biol Med. 2018 Apr;118:44-58. doi: 10.1016/j.freeradbiomed.2018.02.023. Epub 2018 Feb 20.

PMID:
29471108
7.

Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis.

Soukupova J, Bertran E, Peñuelas-Haro I, Urdiroz-Urricelqui U, Borgman M, Kohlhof H, Fabregat I.

Oncotarget. 2017 Nov 30;8(66):110367-110379. doi: 10.18632/oncotarget.22775. eCollection 2017 Dec 15.

8.

Snail mediates crosstalk between TGFβ and LXRα in hepatocellular carcinoma.

Bellomo C, Caja L, Fabregat I, Mikulits W, Kardassis D, Heldin CH, Moustakas A.

Cell Death Differ. 2018 May;25(5):885-903. doi: 10.1038/s41418-017-0021-3. Epub 2017 Dec 11.

9.

Altered TGF-β endocytic trafficking contributes to the increased signaling in Marfan syndrome.

Siegert AM, Serra-Peinado C, Gutiérrez-Martínez E, Rodríguez-Pascual F, Fabregat I, Egea G.

Biochim Biophys Acta Mol Basis Dis. 2018 Feb;1864(2):554-562. doi: 10.1016/j.bbadis.2017.11.015. Epub 2017 Nov 23.

PMID:
29174139
10.

Corrigendum to "European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)" [Redox Biol. 13 (2017) 94-162].

Egea J, Fabregat I, Frapart YM, Ghezzi P, Görlach A, Kietzmann T, Kubaichuk K, Knaus UG, Lopez MG, Olaso-Gonzalez G, Petry A, Schulz R, Vina J, Winyard P, Abbas K, Ademowo OS, Afonso CB, Andreadou I, Antelmann H, Antunes F, Aslan M, Bachschmid MM, Barbosa RM, Belousov V, Berndt C, Bernlohr D, Bertrán E, Bindoli A, Bottari SP, Brito PM, Carrara G, Casas AI, Chatzi A, Chondrogianni N, Conrad M, Cooke MS, Costa JG, Cuadrado A, My-Chan Dang P, De Smet B, Debelec-Butuner B, Dias IHK, Dunn JD, Edson AJ, El Assar M, El-Benna J, Ferdinandy P, Fernandes AS, Fladmark KE, Förstermann U, Giniatullin R, Giricz Z, Görbe A, Griffiths H, Hampl V, Hanf A, Herget J, Hernansanz-Agustín P, Hillion M, Huang J, Ilikay S, Jansen-Dürr P, Jaquet V, Joles JA, Kalyanaraman B, Kaminskyy D, Karbaschi M, Kleanthous M, Klotz LO, Korac B, Korkmaz KS, Koziel R, Kračun D, Krause KH, Křen V, Krieg T, Laranjinha J, Lazou A, Li H, Martínez-Ruiz A, Matsui R, McBean GJ, Meredith SP, Messens J, Miguel V, Mikhed Y, Milisav I, Milković L, Miranda-Vizuete A, Mojović M, Monsalve M, Mouthuy PA, Mulvey J, Münzel T, Muzykantov V, Nguyen ITN, Oelze M, Oliveira NG, Palmeira CM, Papaevgeniou N, Pavićević A, Pedre B, Peyrot F, Phylactides M, Pircalabioru GG, Pitt AR, Poulsen HE, Prieto I, Rigobello MP, Robledinos-Antón N, Rodríguez-Mañas L, Rolo AP, Rousset F, Ruskovska T, Saraiva N, Sasson S, Schröder K, Semen K, Seredenina T, Shakirzyanova A, Smith GL, Soldati T, Sousa BC, Spickett CM, Stancic A, Stasia MJ, Steinbrenner H, Stepanić V, Steven S, Tokatlidis K, Tuncay E, Turan B, Ursini F, Vacek J, Vajnerova O, Valentová K, Van Breusegem F, Varisli L, Veal EA, Yalçın AS, Yelisyeyeva O, Žarković N, Zatloukalová M, Zielonka J, Touyz RM, Papapetropoulos A, Grune T, Lamas S, Schmidt HHHW, Di Lisa F, Daiber A.

Redox Biol. 2018 Apr;14:694-696. doi: 10.1016/j.redox.2017.10.001. Epub 2017 Oct 26. No abstract available.

11.

The level of caveolin-1 expression determines response to TGF-β as a tumour suppressor in hepatocellular carcinoma cells.

Moreno-Càceres J, Caballero-Díaz D, Nwosu ZC, Meyer C, López-Luque J, Malfettone A, Lastra R, Serrano T, Ramos E, Dooley S, Fabregat I.

Cell Death Dis. 2017 Oct 12;8(10):e3098. doi: 10.1038/cddis.2017.469.

12.

Role of the Transforming Growth Factor-β in regulating hepatocellular carcinoma oxidative metabolism.

Soukupova J, Malfettone A, Hyroššová P, Hernández-Alvarez MI, Peñuelas-Haro I, Bertran E, Junza A, Capellades J, Giannelli G, Yanes O, Zorzano A, Perales JC, Fabregat I.

Sci Rep. 2017 Oct 2;7(1):12486. doi: 10.1038/s41598-017-12837-y.

13.

Hybrid polymeric-protein nano-carriers (HPPNC) for targeted delivery of TGFβ inhibitors to hepatocellular carcinoma cells.

Hanafy NAN, Quarta A, Di Corato R, Dini L, Nobile C, Tasco V, Carallo S, Cascione M, Malfettone A, Soukupova J, Rinaldi R, Fabregat I, Leporatti S.

J Mater Sci Mater Med. 2017 Aug;28(8):120. doi: 10.1007/s10856-017-5930-7. Epub 2017 Jul 6.

PMID:
28685231
14.

European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS).

Egea J, Fabregat I, Frapart YM, Ghezzi P, Görlach A, Kietzmann T, Kubaichuk K, Knaus UG, Lopez MG, Olaso-Gonzalez G, Petry A, Schulz R, Vina J, Winyard P, Abbas K, Ademowo OS, Afonso CB, Andreadou I, Antelmann H, Antunes F, Aslan M, Bachschmid MM, Barbosa RM, Belousov V, Berndt C, Bernlohr D, Bertrán E, Bindoli A, Bottari SP, Brito PM, Carrara G, Casas AI, Chatzi A, Chondrogianni N, Conrad M, Cooke MS, Costa JG, Cuadrado A, My-Chan Dang P, De Smet B, Debelec-Butuner B, Dias IHK, Dunn JD, Edson AJ, El Assar M, El-Benna J, Ferdinandy P, Fernandes AS, Fladmark KE, Förstermann U, Giniatullin R, Giricz Z, Görbe A, Griffiths H, Hampl V, Hanf A, Herget J, Hernansanz-Agustín P, Hillion M, Huang J, Ilikay S, Jansen-Dürr P, Jaquet V, Joles JA, Kalyanaraman B, Kaminskyy D, Karbaschi M, Kleanthous M, Klotz LO, Korac B, Korkmaz KS, Koziel R, Kračun D, Krause KH, Křen V, Krieg T, Laranjinha J, Lazou A, Li H, Martínez-Ruiz A, Matsui R, McBean GJ, Meredith SP, Messens J, Miguel V, Mikhed Y, Milisav I, Milković L, Miranda-Vizuete A, Mojović M, Monsalve M, Mouthuy PA, Mulvey J, Münzel T, Muzykantov V, Nguyen ITN, Oelze M, Oliveira NG, Palmeira CM, Papaevgeniou N, Pavićević A, Pedre B, Peyrot F, Phylactides M, Pircalabioru GG, Pitt AR, Poulsen HE, Prieto I, Rigobello MP, Robledinos-Antón N, Rodríguez-Mañas L, Rolo AP, Rousset F, Ruskovska T, Saraiva N, Sasson S, Schröder K, Semen K, Seredenina T, Shakirzyanova A, Smith GL, Soldati T, Sousa BC, Spickett CM, Stancic A, Stasia MJ, Steinbrenner H, Stepanić V, Steven S, Tokatlidis K, Tuncay E, Turan B, Ursini F, Vacek J, Vajnerova O, Valentová K, Van Breusegem F, Varisli L, Veal EA, Yalçın AS, Yelisyeyeva O, Žarković N, Zatloukalová M, Zielonka J, Touyz RM, Papapetropoulos A, Grune T, Lamas S, Schmidt HHHW, Di Lisa F, Daiber A.

Redox Biol. 2017 Oct;13:94-162. doi: 10.1016/j.redox.2017.05.007. Epub 2017 May 18. Review. Erratum in: Redox Biol. 2018 Apr;14 :694-696.

15.

The TGF-β pathway: a pharmacological target in hepatocellular carcinoma?

Fabregat I, Giannelli G; IT-LIVER Consortium.

Hepat Oncol. 2017 Apr;4(2):35-38. doi: 10.2217/hep-2017-0012. Epub 2017 Jul 6. No abstract available.

16.

Transforming growth factor-β-induced plasticity causes a migratory stemness phenotype in hepatocellular carcinoma.

Malfettone A, Soukupova J, Bertran E, Crosas-Molist E, Lastra R, Fernando J, Koudelkova P, Rani B, Fabra Á, Serrano T, Ramos E, Mikulits W, Giannelli G, Fabregat I.

Cancer Lett. 2017 Apr 28;392:39-50. doi: 10.1016/j.canlet.2017.01.037. Epub 2017 Feb 2.

PMID:
28161507
17.

Exploring liver physiology, pathology, TGF-β, EMT, stemness and new developments in liver cancer.

Fabregat I.

Hepat Oncol. 2017 Jan;4(1):9-13. doi: 10.2217/hep-2017-0007. Epub 2017 Jul 6.

18.

The NADPH oxidase NOX4 represses epithelial to amoeboid transition and efficient tumour dissemination.

Crosas-Molist E, Bertran E, Rodriguez-Hernandez I, Herraiz C, Cantelli G, Fabra À, Sanz-Moreno V, Fabregat I.

Oncogene. 2017 May 25;36(21):3002-3014. doi: 10.1038/onc.2016.454. Epub 2016 Dec 12.

19.

The impact of droughts and climate change on sinkhole occurrence. A case study from the evaporite karst of the Fluvia Valley, NE Spain.

Linares R, Roqué C, Gutiérrez F, Zarroca M, Carbonel D, Bach J, Fabregat I.

Sci Total Environ. 2017 Feb 1;579:345-358. doi: 10.1016/j.scitotenv.2016.11.091. Epub 2016 Nov 23.

PMID:
27887826
20.

New Insights into the Crossroads between EMT and Stemness in the Context of Cancer.

Fabregat I, Malfettone A, Soukupova J.

J Clin Med. 2016 Mar 12;5(3). pii: E37. doi: 10.3390/jcm5030037. Review.

21.

The rationale for targeting TGF-β in chronic liver diseases.

Giannelli G, Mikulits W, Dooley S, Fabregat I, Moustakas A, ten Dijke P, Portincasa P, Winter P, Janssen R, Leporatti S, Herrera B, Sanchez A.

Eur J Clin Invest. 2016 Apr;46(4):349-61. doi: 10.1111/eci.12596. Epub 2016 Mar 12. Review.

PMID:
26823073
22.

Caveolin-1-dependent activation of the metalloprotease TACE/ADAM17 by TGF-β in hepatocytes requires activation of Src and the NADPH oxidase NOX1.

Moreno-Càceres J, Mainez J, Mayoral R, Martín-Sanz P, Egea G, Fabregat I.

FEBS J. 2016 Apr;283(7):1300-10. doi: 10.1111/febs.13669. Epub 2016 Feb 22.

23.

TGF-β signalling and liver disease.

Fabregat I, Moreno-Càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G, Ten Dijke P; IT-LIVER Consortium.

FEBS J. 2016 Jun;283(12):2219-32. doi: 10.1111/febs.13665. Epub 2016 Feb 22. Review.

24.

TGF-β1 and TGF-β2 abundance in liver diseases of mice and men.

Dropmann A, Dediulia T, Breitkopf-Heinlein K, Korhonen H, Janicot M, Weber SN, Thomas M, Piiper A, Bertran E, Fabregat I, Abshagen K, Hess J, Angel P, Coulouarn C, Dooley S, Meindl-Beinker NM.

Oncotarget. 2016 Apr 12;7(15):19499-518. doi: 10.18632/oncotarget.6967.

25.

Cross-Talk Between TGF-β and NADPH Oxidases During Liver Fibrosis and Hepatocarcinogenesis.

Crosas-Molist E, Bertran E, Fabregat I.

Curr Pharm Des. 2015;21(41):5964-76. Review.

PMID:
26510436
26.

Apoptosis in liver carcinogenesis and chemotherapy.

Moreno-Càceres J, Fabregat I.

Hepat Oncol. 2015 Oct;2(4):381-397. doi: 10.2217/hep.15.27. Epub 2015 Nov 11. Review.

27.

BMP9-Induced Survival Effect in Liver Tumor Cells Requires p38MAPK Activation.

García-Álvaro M, Addante A, Roncero C, Fernández M, Fabregat I, Sánchez A, Herrera B.

Int J Mol Sci. 2015 Aug 28;16(9):20431-48. doi: 10.3390/ijms160920431.

28.

Dissecting the role of epidermal growth factor receptor catalytic activity during liver regeneration and hepatocarcinogenesis.

López-Luque J, Caballero-Díaz D, Martinez-Palacián A, Roncero C, Moreno-Càceres J, García-Bravo M, Grueso E, Fernández A, Crosas-Molist E, García-Álvaro M, Addante A, Bertran E, Valverde AM, González-Rodríguez Á, Herrera B, Montoliu L, Serrano T, Segovia JC, Fernández M, Ramos E, Sánchez A, Fabregat I.

Hepatology. 2016 Feb;63(2):604-19. doi: 10.1002/hep.28134. Epub 2015 Oct 10.

PMID:
26313466
29.

Role of NADPH oxidases in the redox biology of liver fibrosis.

Crosas-Molist E, Fabregat I.

Redox Biol. 2015 Dec;6:106-11. doi: 10.1016/j.redox.2015.07.005. Epub 2015 Jul 14. Review.

30.

HGF/c-Met signaling promotes liver progenitor cell migration and invasion by an epithelial-mesenchymal transition-independent, phosphatidyl inositol-3 kinase-dependent pathway in an in vitro model.

Suárez-Causado A, Caballero-Díaz D, Bertrán E, Roncero C, Addante A, García-Álvaro M, Fernández M, Herrera B, Porras A, Fabregat I, Sánchez A.

Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2453-63. doi: 10.1016/j.bbamcr.2015.05.017. Epub 2015 May 20.

31.

Mechanisms regulating cell membrane localization of the chemokine receptor CXCR4 in human hepatocarcinoma cells.

Cepeda EB, Dediulia T, Fernando J, Bertran E, Egea G, Navarro E, Fabregat I.

Biochim Biophys Acta. 2015 May;1853(5):1205-18. doi: 10.1016/j.bbamcr.2015.02.012. Epub 2015 Feb 20.

32.

Vascular smooth muscle cell phenotypic changes in patients with Marfan syndrome.

Crosas-Molist E, Meirelles T, López-Luque J, Serra-Peinado C, Selva J, Caja L, Gorbenko Del Blanco D, Uriarte JJ, Bertran E, Mendizábal Y, Hernández V, García-Calero C, Busnadiego O, Condom E, Toral D, Castellà M, Forteza A, Navajas D, Sarri E, Rodríguez-Pascual F, Dietz HC, Fabregat I, Egea G.

Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):960-72. doi: 10.1161/ATVBAHA.114.304412. Epub 2015 Jan 15.

PMID:
25593132
33.

A trifluorinated thiazoline scaffold leading to pro-apoptotic agents targeting prohibitins.

Pérez-Perarnau A, Preciado S, Palmeri CM, Moncunill-Massaguer C, Iglesias-Serret D, González-Gironès DM, Miguel M, Karasawa S, Sakamoto S, Cosialls AM, Rubio-Patiño C, Saura-Esteller J, Ramón R, Caja L, Fabregat I, Pons G, Handa H, Albericio F, Gil J, Lavilla R.

Angew Chem Int Ed Engl. 2014 Sep 15;53(38):10150-4. doi: 10.1002/anie.201405758. Epub 2014 Sep 5.

PMID:
25196378
34.

A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.

Fernando J, Malfettone A, Cepeda EB, Vilarrasa-Blasi R, Bertran E, Raimondi G, Fabra À, Alvarez-Barrientos A, Fernández-Salguero P, Fernández-Rodríguez CM, Giannelli G, Sancho P, Fabregat I.

Int J Cancer. 2015 Feb 15;136(4):E161-72. doi: 10.1002/ijc.29097. Epub 2014 Aug 4.

35.

Caveolin-1 is required for TGF-β-induced transactivation of the EGF receptor pathway in hepatocytes through the activation of the metalloprotease TACE/ADAM17.

Moreno-Càceres J, Caja L, Mainez J, Mayoral R, Martín-Sanz P, Moreno-Vicente R, Del Pozo MÁ, Dooley S, Egea G, Fabregat I.

Cell Death Dis. 2014 Jul 17;5:e1326. doi: 10.1038/cddis.2014.294.

36.

Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinoma.

Rani B, Cao Y, Malfettone A, Tomuleasa C, Fabregat I, Giannelli G.

World J Gastroenterol. 2014 Apr 21;20(15):4128-40. doi: 10.3748/wjg.v20.i15.4128. Review.

37.

Polμ deficiency increases resistance to oxidative damage and delays liver aging.

Escudero B, Lucas D, Albo C, Dhup S, Bacher JW, Sánchez-Muñoz A, Fernández M, Rivera-Torres J, Carmona RM, Fuster E, Carreiro C, Bernad R, González MA, Andrés V, Blanco L, Roche E, Fabregat I, Samper E, Bernad A.

PLoS One. 2014 Apr 1;9(4):e93074. doi: 10.1371/journal.pone.0093074. eCollection 2014.

38.

The NADPH oxidase NOX4 inhibits hepatocyte proliferation and liver cancer progression.

Crosas-Molist E, Bertran E, Sancho P, López-Luque J, Fernando J, Sánchez A, Fernández M, Navarro E, Fabregat I.

Free Radic Biol Med. 2014 Apr;69:338-47. doi: 10.1016/j.freeradbiomed.2014.01.040. Epub 2014 Feb 6.

PMID:
24509161
39.

TGF-beta signaling in cancer treatment.

Fabregat I, Fernando J, Mainez J, Sancho P.

Curr Pharm Des. 2014;20(17):2934-47. Review.

PMID:
23944366
40.

BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells.

Herrera B, García-Álvaro M, Cruz S, Walsh P, Fernández M, Roncero C, Fabregat I, Sánchez A, Inman GJ.

PLoS One. 2013 Jul 23;8(7):e69535. doi: 10.1371/journal.pone.0069535. Print 2013.

41.

Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.

Dituri F, Mazzocca A, Fernando J, Peidrò FJ, Papappicco P, Fabregat I, De Santis F, Paradiso A, Sabbà C, Giannelli G.

PLoS One. 2013 Jun 27;8(6):e67109. doi: 10.1371/journal.pone.0067109. Print 2013. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/c943a596-3965-4a5b-a27c-55c16685ea32. Peidrò, Fernando Juan [corrected to Fernando, Joan]. PLoS One. 2014;9(6):e100604.

42.

Overactivation of the TGF-β pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells.

Bertran E, Crosas-Molist E, Sancho P, Caja L, Lopez-Luque J, Navarro E, Egea G, Lastra R, Serrano T, Ramos E, Fabregat I.

Hepatology. 2013 Dec;58(6):2032-44. doi: 10.1002/hep.26597. Epub 2013 Oct 11.

PMID:
23813475
43.

Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy.

López-Erauskin J, Galino J, Ruiz M, Cuezva JM, Fabregat I, Cacabelos D, Boada J, Martínez J, Ferrer I, Pamplona R, Villarroya F, Portero-Otín M, Fourcade S, Pujol A.

Hum Mol Genet. 2013 Aug 15;22(16):3296-305. doi: 10.1093/hmg/ddt186. Epub 2013 Apr 20.

PMID:
23604518
44.

Mouse hepatic oval cells require Met-dependent PI3K to impair TGF-β-induced oxidative stress and apoptosis.

Martínez-Palacián A, del Castillo G, Suárez-Causado A, García-Álvaro M, de Morena-Frutos D, Fernández M, Roncero C, Fabregat I, Herrera B, Sánchez A.

PLoS One. 2013;8(1):e53108. doi: 10.1371/journal.pone.0053108. Epub 2013 Jan 2.

45.

ROS production is essential for the apoptotic function of E2F1 in pheochromocytoma and neuroblastoma cell lines.

Espada L, Meo-Evoli N, Sancho P, Real S, Fabregat I, Ambrosio S, Tauler A.

PLoS One. 2012;7(12):e51544. doi: 10.1371/journal.pone.0051544. Epub 2012 Dec 12.

46.

NADPH oxidase NOX4 mediates stellate cell activation and hepatocyte cell death during liver fibrosis development.

Sancho P, Mainez J, Crosas-Molist E, Roncero C, Fernández-Rodriguez CM, Pinedo F, Huber H, Eferl R, Mikulits W, Fabregat I.

PLoS One. 2012;7(9):e45285. doi: 10.1371/journal.pone.0045285. Epub 2012 Sep 26.

47.

BMPS and liver: more questions than answers.

Herrera B, Sánchez A, Fabregat I.

Curr Pharm Des. 2012;18(27):4114-25. Review.

PMID:
22630083
48.

Cell fusion reprogramming leads to a specific hepatic expression pattern during mouse bone marrow derived hepatocyte formation in vivo.

Quintana-Bustamante O, Grueso E, Garcia-Escudero R, Arza E, Alvarez-Barrientos A, Fabregat I, Garcia-Bravo M, Meza NW, Segovia JC.

PLoS One. 2012;7(3):e33945. doi: 10.1371/journal.pone.0033945. Epub 2012 Mar 23.

49.

Protein-tyrosine phosphatase 1B (PTP1B) deficiency confers resistance to transforming growth factor-β (TGF-β)-induced suppressor effects in hepatocytes.

Ortiz C, Caja L, Bertran E, Gonzalez-Rodriguez Á, Valverde ÁM, Fabregat I, Sancho P.

J Biol Chem. 2012 May 4;287(19):15263-74. doi: 10.1074/jbc.M111.303958. Epub 2012 Mar 16.

50.

EGFR is dispensable for c-Met-mediated proliferation and survival activities in mouse adult liver oval cells.

Martínez-Palacián A, del Castillo G, Herrera B, Fernández M, Roncero C, Fabregat I, Sánchez A.

Cell Signal. 2012 Feb;24(2):505-13. doi: 10.1016/j.cellsig.2011.09.031. Epub 2011 Oct 7.

PMID:
22001397

Supplemental Content

Loading ...
Support Center